Global Leading Market Research Publisher QYResearch announces the release of its latest report “Dissolution Tester for Pharmaceutical – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Dissolution Tester for Pharmaceutical market, including market size, share, demand, industry development status, and forecasts for the next few years.
Second paragraph (sample PDF request, link kept as text, no hyperlink):
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098177/dissolution-tester-for-pharmaceutical
Executive Summary
The global market for Dissolution Tester for Pharmaceutical was valued at US$ 536 million in 2025 and is projected to reach US$ 668 million by 2032, growing at a CAGR of 3.3%. In 2024, global production reached approximately 125,440 units with an average price of US$ 4,100 per unit. A dissolution tester measures drug release rate and extent from solid dosage forms (tablets, capsules) into a suitable medium (simulated gastric/intestinal fluid) under standardized conditions. It simulates GI tract physiology to evaluate bioavailability and predict in vivo performance. Key components: thermostatic water bath (37°C ±0.5°C), dissolution vessels, stirring devices (paddles USP App.2, baskets USP App.1), control unit, and automated sampling with UV-Vis or HPLC integration.
Core user pain points addressed include: batch-to-batch dissolution variability (QC failures), slow manual sampling (operator-dependent), regulatory compliance (USP, EP, JP, FDA), and method development time (R&D). Dissolution testers resolve these through automated sampling (reproducible, time-point accuracy), temperature control (37°C ±0.2°C), and USP/EP/JP compliance (apparatus calibration, vessel geometry).
Embedded Core Keywords (3–5)
- Drug release rate – QC dissolution specification
- USP Apparatus 1 (basket) – for capsules, floating tablets
- USP Apparatus 2 (paddle) – for tablets, most common
- Dissolution medium – simulated gastric/intestinal fluid (SGF, SIF)
- Bioavailability prediction – in vitro-in vivo correlation (IVIVC)
1. Market Size and Growth (2025-2032)
| Year | Market Value (US$ million) | Units | Avg Price (US$) | CAGR |
|---|---|---|---|---|
| 2024 | — | 125,440 | 4,100 | — |
| 2025 | 536 | — | — | — |
| 2032 | 668 | — | — | 3.3% |
Growth drivers:
- Generic drug development (requires dissolution profile for FDA/EMA approval, Q1/Q2 sameness)
- Biopharmaceutics Classification System (BCS) biowaivers (BCS Class I, III)
- Quality by Design (QbD) in pharmaceutical manufacturing
- USP/EP/JP harmonization (increased testing requirements)
- Post-approval changes (site transfer, scale-up, excipient change)
Exclusive observation (Q1 2026): BCS biowaivers (BCS Class I, III) allow waiver of in vivo bioequivalence studies based on rapid dissolution (>85% in 30 minutes). This increases demand for dissolution testers for initial profile characterization.
2. Dissolution Methods (USP Apparatus)
| Apparatus | Type | Medium Volume | Agitation Speed (rpm) | Typical Dosage Form | Advantages | Disadvantages |
|---|---|---|---|---|---|---|
| Apparatus 1 (Basket) | Rotating basket (wire mesh) | 500-1000 mL | 50-100 | Capsules (swelling), floating tablets, sustained-release (non-disintegrating) | Suitable for floating/swelling dosage forms | Air bubble entrapment, mesh clogging |
| Apparatus 2 (Paddle) | Rotating paddle (flat blade) | 500-1000 mL | 50-75 | Tablets (most common), immediate-release, disintegrating | Most widely used, validated (pharmacopeia) | Coning (undissolved powder mound under paddle) |
| Apparatus 3 (Reciprocating Cylinder) | Cylinder moves vertically | 200-250 mL per station | 5-40 dips/min | Beads, particles, implants | Medium volume change, pH change profile | Less common (specialized) |
| Apparatus 4 (Flow-Through) | Flow-through cell (continuous flow of fresh medium) | Variable | Flow rate (mL/min) | Poorly soluble drugs (API) | Sink conditions maintained (continuous fresh medium) | Complex setup, limited adoption |
User case (2025, Generic tablet QC – Apparatus 2): A generic manufacturer tests metformin tablets (500mg) for QA batch release. Dissolution conditions: USP App.2, 900 mL pH 6.8 buffer (simulated intestinal fluid), 50 rpm, 60 minutes. Acceptance criteria: Q=85% (not less than 85% dissolved). Sampling timepoints: 15, 30, 45, 60 minutes. Automated sampling with UV detection (266nm). Batch passes (98% at 60 min). FDA filing.
User case (2025, Capsule – Apparatus 1): A company tests enteric-coated capsules (omeprazole). Medium: 0.1N HCl (2 hours, simulate gastric), then pH 6.8 phosphate buffer (45 minutes). USP App.1 (baskets, 100 rpm). Capsules remain in basket (do not float). Dissolution at 45 minutes in buffer: >80% (pass). Delayed release specification verified.
3. Tablet vs. Capsule Dissolution Testing
| Parameter | Tablet Dissolution Tester | Capsule Dissolution Tester |
|---|---|---|
| Preferred USP Apparatus | Apparatus 2 (paddle) | Apparatus 1 (basket) or Apparatus 2 |
| Sample preparation | Tablet dropped directly into vessel (may disintegrate) | Capsule dropped into basket (App.1) or with sinker (App.2, prevents floating) |
| Coning issue | Yes (powder mound under paddle, add sinker) | No (capsule shell contains powder, no coning) |
| Air bubble entrapment | Rare | Yes (within basket mesh, remove manually) |
| Typical test duration | 30-60 minutes (immediate-release) | 45-120 minutes (delayed-release, enteric-coated) |
| Common dosage forms | Immediate-release tablets, chewable, orally disintegrating | Hard gelatin capsules, softgels, enteric-coated capsules |
User case (2025, Softgel capsule dissolution – Sinker): A softgel capsule (Vitamin E) floats in medium (App.2). Added sinker (helical wire, 0.5g) to submerge capsule. Dissolution: 75 rpm, 60 minutes, 900 mL pH 6.8 buffer. Sinker ensures capsule remains in paddle agitation zone. Pass specification: >75% dissolved.
4. Dissolution Medium and Conditions
| Medium Type | pH | Composition | Simulates | Application |
|---|---|---|---|---|
| Simulated Gastric Fluid (SGF) without pepsin | 1.2 | 0.1N HCl, NaCl | Fasted stomach (gastric fluid) | Acid-resistant formulations, enteric-coated (first 2 hours) |
| Simulated Intestinal Fluid (SIF) without pancreatin | 6.8 | KH₂PO₄, NaOH (phosphate buffer) | Fasted small intestine | Most immediate-release tablets (pH 6.8) |
| Acetate buffer | 4.5 | Sodium acetate, acetic acid | Fed stomach (pH 4-5) | Weak base APIs (solubility pH-dependent) |
| Water | 7.0 (approx) | Deionized water | Simple screening | BCS Class I (high solubility) |
| Surfactant (SDS) added | Variable | 0.1-1% sodium dodecyl sulfate | Poorly soluble API | Enhances wettability, sink conditions |
Technical nuance: Sink conditions: Dissolution medium volume must be at least 3x saturation solubility of API. For poorly soluble drugs, add surfactant (SDS) or increase volume (USP Apparatus 4 flow-through). USP criteria: >85% dissolved in 60 minutes for immediate-release (requires sink conditions).
5. Competitive Landscape
Key vendors: ERWEKA (Verder, Germany), Infitek (Germany), SOTAX (Switzerland, global leader), Agilent (US, HPLC integration), JASCO Global (Japan), Copley Scientific (UK), Distek (US), Koehler (US), Torontech (Canada), Teledyne LABS (US), Raytor Instruments (India), United Pharmatek (US), LABOAO (China), BIOBASE (China), SaintyCo (China), Scitek Global (China), Electrolab (India), Labindia Analytical (India).
Market structure: SOTAX and Agilent dominate premium segment (automated systems, HPLC integration, regulatory compliance). ERWEKA, Distek, Copley are established European/US competitors. Chinese manufacturers (LABOAO, BIOBASE, SaintyCo, Scitek) dominate low-cost domestic market (40-50% below Western pricing) for manual or semi-automated systems.
| Company | Region | Automation Level | Key Differentiator |
|---|---|---|---|
| SOTAX | Switzerland/Global | Fully automated (AT 70, 1200) | USP/EP/JP compliance, global support |
| Agilent | US/Global | Fully automated (708-DS, 850-DS) | Integration with UV-Vis (Cary) |
| ERWEKA | Germany/Global | Semi to fully automated | Modular systems |
| LABOAO / BIOBASE | China | Manual/semi-automated | Low cost ($2-4k vs. SOTAX $10-25k) |
Exclusive insight (2026): Chinese dissolution testers (LABOAO, BIOBASE, SaintyCo) are gaining export share in Asia-Pacific, Middle East, Africa, Latin America for QC labs (generic manufacturers, emerging markets). Price: $2,000-5,000 (vs. SOTAX/Agilent $10,000-30,000). Accuracy adequate for USP compliance (pharmacopeia). Premium brands dominate regulated markets (US, EU, Japan) and pharma R&D.
6. Automation Levels and Compliance
| Level | Sampling | Temperature Control | Vessel Centering | Data Integrity | Typical Use | Price Range |
|---|---|---|---|---|---|---|
| Manual | Manual pipette (operator-dependent) | Manual (thermometer, heater) | Manual centering | Paper logbook, notebook | Teaching labs, very low volume | $2k-5k |
| Semi-Automated | Manual with timer alarm | Digital temperature display (calibrated) | Fixed vessel alignment (tooling) | Digital recording, printout | QC (generic, emerging markets) | $5k-10k |
| Fully Automated (21 CFR Part 11) | Autosampler (peristaltic or syringe), time-point accuracy ±1 second | PID control (±0.2°C) integrated with audit trail | Automatic centering, alignment | Electronic records, audit trail, electronic signatures, user access control | R&D, QC (regulated markets: US, EU, Japan) | $15k-40k+ |
User case (2025, QC lab – Semi-automated): A generic manufacturer in India (export to Africa) uses semi-automated dissolution tester ($8k, LABOAO). Digital temperature display, autosampler (6 vessels), QC manager records results in electronic logbook (paper backup). Acceptable for local registration (not US, EU).
User case (2025, R&D – Fully automated, 21 CFR Part 11): A US R&D lab (NDA submission) uses SOTAX fully automated system ($35k). USP App.2 (paddle), 12 vessels, 37°C ±0.1°C, autosampler with UV detection. 21 CFR Part 11 compliant: audit trail (all user actions, temperature deviations, sampling times), electronic signatures, access control (password, role-based). Data accepted by FDA.
7. Forecast and Analyst Takeaways (2026–2032)
Growth projections: 3.3% CAGR. Generic drug development (esp. in Asia) driving volume. Automation and 21 CFR Part 11 compliance driving value (premium segment). Asia-Pacific fastest-growing (5-6% CAGR, China, India).
| Region | 2025 Share | Key Drivers |
|---|---|---|
| North America | 25-30% | R&D, generic substitution, FDA compliance |
| Europe | 25-30% | EP compliance, generics |
| Asia-Pacific | 30-35% (largest) | China, India generic manufacturing & export |
| RoW (LatAm, Africa, Middle East) | 10-15% | Local generic production |
Exclusive recommendations:
- For QC labs (regulated markets: US, EU, Japan – ANDA, NDA): Fully automated dissolution tester with 21 CFR Part 11 compliance (electronic records, audit trail, electronic signatures, user access control). SOTAX or Agilent. Autosampler essential for time-point accuracy (FDA inspection). Annual calibration (temperature, rotation speed, alignment) documented.
- For QC labs (emerging markets, generic export to non-regulated): Semi-automated dissolution tester (LABOAO, BIOBASE, SaintyCo) at 40-50% lower cost. Digital temperature display, autosampler (reduces sampling error). Acceptable for local registration (Africa, SE Asia, Latin America). Not for US/EU filing.
- For R&D (formulation development): Automated system with UV-Vis or HPLC integration (Agilent 708-DS with Cary 60). Multiple vessels (8 or 12 vessels). Media degassing (removes dissolved air, reduces variability). BCS biowaiver studies (rapid dissolution >85% in 30 minutes).
- For training labs (universities): Manual dissolution testers (basic, low cost). Teach principle (drug release rate, sink conditions, USP apparatus). Not for regulated QC.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
